LiveDrop

The world’s first all-integrated instrument based on droplet microfluidics tech with the ability to detect and select biological cells such as therapeutic antibody-producing cells like monoclonal antibodies, cancer cells, rare immune cells, stem cells and fragile cells that are difficult to manipulate with classical techniques such as flow cytometers (FACS: “Fluorescence-activated cell sorter”) and multiwell plates.

LiveDrop has raised €2.3M across 1 funding round from 3 investors, most recently a round in May 2022. Based in Brussels, Belgium; active in Healthtech. Data as of 28 Oct 2026.